Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

about

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

Item

http://www.wikidata.org/entity/Q36372611

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@ast

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@en

type

Item

label

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@ast

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@en

prefLabel

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@ast

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@en

P1476

Real-World Data on Prognostic ...... ted with First-Line Gefitinib.

@en

P2093

Chao-Chi Ho

http://www.w3.org/2001/XMLSchema#string

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

James Chih-Hsin Yang

http://www.w3.org/2001/XMLSchema#string

Jin-Shing Chen

http://www.w3.org/2001/XMLSchema#string

Jin-Yuan Shih

http://www.w3.org/2001/XMLSchema#string

Kuan-Yu Chen

http://www.w3.org/2001/XMLSchema#string

Zhong-Zhe Lin

http://www.w3.org/2001/XMLSchema#string

Zong-Han Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Extrahepatic manifestations of chronic hepatitis C virus infection

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

P304

1075-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2016-0331

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chong-Jen Yu

Wei-Yu Liao

P577

2017-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28507206

http://www.w3.org/2001/XMLSchema#string

P932

5599189

http://www.w3.org/2001/XMLSchema#string